Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 5
2010 3
2011 6
2012 8
2013 7
2014 7
2015 13
2016 13
2017 19
2018 20
2019 18
2020 24
2021 21
2022 21
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
In Reply.
Tanizaki J, Chiba Y, Haratani K, Hayashi H, Nakagawa K. Tanizaki J, et al. Among authors: chiba y. J Thorac Oncol. 2018 May;13(5):e86-e87. doi: 10.1016/j.jtho.2018.02.003. J Thorac Oncol. 2018. PMID: 29703548 Free article. No abstract available.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: chiba y. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: chiba y. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K. Yonesaka K, et al. Among authors: chiba y. Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17. Clin Cancer Res. 2022. PMID: 34921025
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, Yokoyama T, Fukuda Y, Chiba Y, Kato R, Tanizaki J, Tanaka K, Takeda M, Ogura T, Ishida T, Ito A, Nakagawa K. Isomoto K, et al. Among authors: chiba y. Clin Cancer Res. 2020 Apr 15;26(8):2037-2046. doi: 10.1158/1078-0432.CCR-19-2027. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937613
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Yamamoto N, et al. Among authors: chiba y. J Clin Oncol. 2010 Aug 10;28(23):3739-45. doi: 10.1200/JCO.2009.24.5050. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625120 Clinical Trial.
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T, Chamoto K, Suzuki S, Kanemura H, Mitani S, Tanaka K, Kawakami H, Kishimoto Y, Haku Y, Ito K, Sato T, Suminaka C, Yamaki M, Chiba Y, Yaguchi T, Omori K, Kobayashi T, Nakagawa K, Honjo T, Hayashi H. Kurosaki T, et al. Among authors: chiba y. Front Immunol. 2023 Dec 11;14:1325462. doi: 10.3389/fimmu.2023.1325462. eCollection 2023. Front Immunol. 2023. PMID: 38149256 Free PMC article.
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Watanabe K, Maeda S, Yokoe T, Imamura CK, Matsumoto K, Iwasa T, Chiba Y, Takiguchi D, Takano T. Sakai H, et al. Among authors: chiba y. BMJ Open. 2023 Apr 3;13(4):e070304. doi: 10.1136/bmjopen-2022-070304. BMJ Open. 2023. PMID: 37012013 Free PMC article.
167 results